BACKGROUND
Allogeneic hematopoietic cell transplantation (HCT) is the only curative therapy for myelofibrosis (MF), and donor selection remains one of the few modifiable determinants of outcome. As the unrelated donor pool ages, the impact of donor age in matched unrelated donor (MUD) HCT for MF has become increasingly...
K. Sakatoku, Yutaka Shimazu, Makoto Murata et al.· Transplantation and Cellular...· 0 citations
We retrospectively analysed clinical outcomes of 152 patients with non-malignant diseases (NMDs) who underwent a second allogeneic haematopoietic stem cell transplantation (HSCT), using a composite end-point, graft-versus-host disease (GVHD)-free, relapse (i.e. graft failure)-free and subsequent transplant-free surviva...
Maiko Shimomura, Koji Kawaguchi, Shohei Yamamoto et al.· British Journal of Haematolo...· 0 citations
Although recent studies suggested an enhanced graft-versus-tumor (GVT) effect with cord blood transplantation (CBT), higher rates of engraftment failure, acute graft-versus-host disease (GVHD), and infections, including cytomegalovirus (CMV), contribute to increased nonrelapse mortality (NRM). Thus, further optimizatio...
Shunto Kawamura, Y. Akahoshi, Hideaki Nakasone et al.· Transplantation and Cellular...· 0 citations
The effect of different maintenance therapies on outcome after autologous hematopoietic cell transplantation (AHCT) was analyzed in newly diagnosed multiple myeloma (NDMM) patients using global real-world data. NDMM patients transplanted between 2013 and 2017 were selected from the Worldwide Network for Blood and Marro...
Andrew J. Cowan, L. Gras, R. Cassano et al.· Haematologica· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.